Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

acute kidney injury

- PMLiVE

New blood test to reduce heart attacks and death rates in A&E heart patients

The test could improve diagnosis for one in five patients with a heart muscle injury

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

Landscape review reveals £1.1bn of UK funding for rare diseases

The report focuses on future funding and needs for those with rare diseases

- PMLiVE

NIHR and MRC establish UK Rare Disease Research Platform with £14m investment

The platform brings together expertise from across the UK rare disease research system

- PMLiVE

Novartis to acquire Chinook Therapeutics for approximately $3.5bn

The deal marks a notable expansion to the Swiss drugmaker's kidney disease pipeline

- PMLiVE

New research shows potential to treat kidney disease with common medicines

Acute kidney injuries cause around 20% of all emergency hospital admissions in the UK

- PMLiVE

UK Government commit £50m to motor neurone disease research

The pledged funding is being placed into the hands of researchers ‘as quickly as possible’

- PMLiVE

New research shows potential to diagnose myocarditis with routine blood tests

Currently, the gold standard method in diagnosing the condition is a heart biopsy

- PMLiVE

BHF announces drug combination could delay need for high-risk surgery in patients with Marfan syndrome

An estimated one million people worldwide live with the genetic condition, for which there is currently no cure

- PMLiVE

Six UK universities receive grant for research into motor neurone disease

The grant was given by the Medical Research Council and the National Institute for Health and Care Research, along with charities LifeArc, MND Association, My Name’5 Doddie Foundation and MND...

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

Moving Away from Hospital-Centered Care: Barriers & Opportunities

David Barthel, CEO of Health Logic Interactive Inc., discusses their lab-on-chip, point-of-care platform technology for CKD. He also explores the issues with the hospital-centered model of care, shares his tips...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links